Aquestive Therapeutics Opens New Labs at New Brunswick
The pharmaceutical firm's move into pre-built space at the HELIX helps bypass standard lab construction costs and timelines.
Updated on Oct. 16, 2026 in Healthcare
Live Poll
Does clustering pharmaceutical and research firms in your area improve the local economy?
Aquestive Therapeutics has relocated its research and development operations to a new 5,000-square-foot lab suite at the HELIX in New Brunswick. The move comes as the company advances its regulatory pipeline, with the FDA recently accepting its resubmission for the drug Anaphylm.
Why it matters
By moving into ready-to-use facilities like the H1 building, life sciences operators can avoid the substantial capital expenditures and lengthy construction timelines required to build out bespoke research space. This strategy enables faster scaling and access to centralized talent hubs for growing firms.
Aquestive Therapeutics secured a 5,000-square-foot facility on the 10th floor of the H1 building. The firm currently markets its products across 6 continents, marking a significant expansion from its headquarters in Warren.
The players
Aquestive Therapeutics
A pharmaceutical company headquartered in Warren that develops and manufactures medical products currently marketed across 6 continents.
New Brunswick Development Corp.
The local entity responsible for the planning and development of the HELIX project in New Brunswick.
JLL
A global commercial real estate services firm that marketed the enterprise suites at the HELIX and brokered the lab space transaction.
The details
The H1 building at 20 French St. provides pre-constructed laboratory environments designed to eliminate the standard delay of installing specialized mechanical and ventilation systems. By opting for these enterprise suites, Aquestive Therapeutics leverages existing infrastructure to facilitate immediate collaboration within the growing New Brunswick life sciences ecosystem.
Timeline
October 15, 2026: Move and FDA application acceptance announced.
March 15, 2027: FDA Prescription Drug User Fee Act goal date for the Anaphylm application.
Market Landscape
The FDA's assignment of a goal date for Anaphylm follows the established statutory review timelines mandated under the Prescription Drug User Fee Act. This regulatory milestone provides a clear horizon for the company’s clinical development progress.
Operators in the life sciences sector should evaluate the availability of plug-and-play lab environments when planning expansion to minimize startup costs. Companies should also track the March 15, 2027, FDA milestone as a key indicator of market regulatory timing.
The takeaway
Utilizing pre-built lab spaces allows companies to prioritize capital for R&D rather than facility construction. Monitor local development project updates to identify future opportunities for accessing consolidated life sciences infrastructure.
What happens next
The FDA has set a Prescription Drug User Fee Act goal date of March 15, 2027, for the company's New Drug Application regarding Anaphylm.
Further reading
For more on industry facility trends, visit the Healthcare section.
Source note: This article includes information reported by NJBIZ.
Live Poll
Does clustering pharmaceutical and research firms in your area improve the local economy?
